NBSE News and Press, NeuBase Therapeutics Inc. From 03/09/21

PITTSBURGH, March 09, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, ...

NeuBase Therapeutics (NBSE): FQ1 GAAP EPS of -$0.18 beats by $0.05.At Dec. 31, 2020, the Company had cash and equivalents of ~$28.0M.Press Release For further details see: NeuBase Therapeutics EPS beats by $0.05

NeuBase Therapeutics (NBSE) has climbed ~14.4% in pre-market trading after the company announced a binding agreement to acquire infrastructure, programs, and intellectual property for several peptide-nucleic acid (“PNA”) scaffolds from Vera Therapeutics.The new pe...

NeuBase Therapeutics (NASDAQ: NBSE) ended the week on a real sugar high, rising by nearly 17% on Friday. This was due to a glowing note about the biotech from one of its more prominent investors. The praise came from Greenlight Capital, the hedge fund run by noted investor David Ein...

Green Light Capital is a privately owned hedge fund sponsor. The firm invests in the public equity and fixed income markets of the United States. It primarily invests in value stocks of companies. The firm employs a fundamental analysis with a market neutral strategy to make its investmen...

Assured Guaranty (AGO) fell 4.1% after Greenlight's David Einhorn revealed that he's short, according to a copy of a 4Q letter.Greenlight short based on original thesis the company has "several billion dollars of likely embedded losses" on its exposure to Puerto Rico. Greenlight ori...

NeuBase Therapeutics (NBSE): FY GAAP EPS of -$0.89 in-line.Cash and equivalents of $32M.Press Release For further details see: NeuBase Therapeutics EPS in-line

Registration For This FREE Tribe Public Presentation and Q&A Event Is Now Open at NeuBase22.TribePublic.com SAN FRANCISCO, CA / ACCESSWIRE / December 18, 2020 / Tribe Public announced today that Dietrich Stephan, Ph.D., Chief Executive Officer of NeuBase Therapeutics, Inc. (NASDAQ...

Sio Gene Therapies (SIOX) +42% on positive AXO-AAV-GM1 data in nerve cell disorder.Good Times Restaurants (GTIM) +27% on Q4 results.Tilray (TLRY) +27% as company to combine with Aphria to create largest global cannabis company.DAVIDsTEA (DTEA) +25% on Q3 results.NeuBa...

NeuBase Therapeutics (NBSE) announces positive in vitro and in vivo preclinical data for its PATrOL-enabled anti-gene therapies for the treatment of myotonic dystrophy type 1 (DM1).These new data show that PATrOL-enabled Compound A can rapidly resolve mis-splicing without negatively impacting...